Employing advanced analytics and artificial intelligence in rare-disease pharmacovigilance
By Lucy Fulford-Smith, Head of Pharmacovigilance & Medical Services [...]
The limits of traditional pharmacovigilance in rare diseases
By Lucy Fulford-Smith, Head of Pharmacovigilance & Medical Services [...]
How to choose the right functional service provider operating model for scaling your drug development programme
For small to mid‑sized biotech and pharma companies, building [...]
Designing early-phase clinical trials for advanced therapeutics: key considerations and challenges
Entering early‑phase clinical development with a novel advanced therapeutic [...]
TMC announces three specialist service lines to accelerate drug development for biotech and pharma companies
London, UK — 5 November 2025 TMC, a global [...]
Panel | Breaking into Europe with an integrated pharma model
Breaking into Europe Sweetening launch complexity with an integrated [...]
How to craft an effective EU pharma strategy for small to mid-sized biotech and pharma companies
The European market offers a large patient base, strong [...]
How to integrate early access programmes into your pharma market access strategy
Access is everything for rare disease patients, who often [...]
Medical affairs vs drug commercialisation: understanding the line between science and sales
The line between medical affairs and drug commercialisation functions [...]